Journal Home > Volume 14 , Issue 1

Multidrug resistance (MDR) restricts chemotherapy efficacy due to P-glycoprotein (P-gp) mediated drug efflux, whereas current approaches to suppressing P-gp expression suffer from intrinsic challenges, such as low transfection, high toxicity and poor specificity. Here, hollow ferric-tannic acid complex nanocapsules (HFe-TA), which can be effectively degraded by the reaction with adenosine triphosphate (ATP), are synthesized for the delivery of glucose oxidase (GOx) and doxorubicin (DOX) for tumor treatment. The findings indicate that the intracellular ATP is significantly decreased due to the combined effect of HFe-TA degradation and GOx-mediated glucose consumption. Along with this ATP down-regulation, P-gp expression of tumor cells is suppressed remarkably, which in turn promotes the intracellular accumulation and anticancer efficacy of DOX. In addition, the production of •OH by Fe ions released from HFe-TA is promoted by the by-products of the oxidation of glucose process by GOx. In consequence, HFe-TA nanocapsules loaded with DOX and GOx enable significant inhibition effect to tumors both in vitro and in vivo due to the synergistic effect of cascade reactions. This study has therefore provided an alternative therapeutic platform for effective tumor inhibition with the potential in overcoming intrinsic MDR.

File
12274_2020_3071_MOESM1_ESM.pdf (6.1 MB)
Publication history
Copyright
Acknowledgements

Publication history

Received: 17 July 2020
Revised: 17 August 2020
Accepted: 22 August 2020
Published: 05 January 2021
Issue date: January 2021

Copyright

© Tsinghua University Press and Springer-Verlag GmbH Germany, part of Springer Nature

Acknowledgements

This work was financially supported by the National Natural Science Foundation of China (Nos. 51672247 and 51902288), Provincial Key research program of Zhejiang Province (No. 2020C04005), "111" Program funded by Education Ministry of China and Sate Bureau of Foreign Experts Affairs (No. B16043), China Postdoctoral Science Foundation (No. 2018M640555), Fundamental Research Funds for the Central Universities and ZJU-Hangzhou Global Scientific and Technological Innovation Center.

Return